Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, Nasu A, Ogawa C, Kojima Y, Hasebe C, Wada S, Uchida Y, Sohda T, Suzuki H, Yoshida H, Kusakabe A, Tamada T, Kobashi H, Mitsuda A, Kondo M, Shigeno M, Ide Y, Morita A, Kitamura T, Abe T, Izumi N.
Akahane T, et al. Among authors: kurosaki m.
Hepatol Res. 2019 Mar;49(3):264-270. doi: 10.1111/hepr.13246. Epub 2018 Oct 20.
Hepatol Res. 2019.
PMID: 30171740